• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.血清C'1酯酶抑制剂对纤溶酶、血浆激肽释放酶、血浆通透因子及补体第一成分的C'1r亚成分的抑制作用。
J Exp Med. 1969 Feb 1;129(2):315-31. doi: 10.1084/jem.129.2.315.
2
The conversion of C'IS to C'1 esterase by plasmin and trypsin.纤溶酶和胰蛋白酶将C'IS转化为C'1酯酶。
J Exp Med. 1967 Feb 1;125(2):337-58. doi: 10.1084/jem.125.2.337.
3
The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r.补体1r（C'1r）的酶性质。补体1s（C'1s）转化为补体1酯酶以及补体1r对氨基酸酯的消化作用。
J Exp Med. 1968 Oct 1;128(4):571-93. doi: 10.1084/jem.128.4.571.
4
Chromatographic resolution of the first component of human complement into three activities.将人类补体的第一成分通过色谱法分离为三种活性。
J Exp Med. 1963 Jun 1;117(6):983-1008. doi: 10.1084/jem.117.6.983.
5
COMPLEMENT AS A MEDIATOR OF INFLAMMATION. ENHANCEMENT OF VASCULAR PERMEABILITY BY PURIFIED HUMAN C'1 ESTERASE.补体作为炎症介质。纯化的人C1酯酶对血管通透性的增强作用。
J Exp Med. 1963 Nov 1;118(5):681-98. doi: 10.1084/jem.118.5.681.
6
Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro.遗传性血管性水肿血浆中补体C1酯酶体外激活机制
J Exp Med. 1968 Mar 1;127(3):411-29. doi: 10.1084/jem.127.3.411.
7
THE MACROMOLECULAR NATURE OF THE FIRST COMPONENT OF HUMAN COMPLEMENT.人类补体第一成分的大分子性质
J Exp Med. 1964 Apr 1;119(4):593-613. doi: 10.1084/jem.119.4.593.
8
C'1 ESTERASE EFFECT ON ACTIVITY AND PHYSICOCHEMICAL PROPERTIES OF THE FOURTH COMPONENT OF COMPLEMENT.C1酯酶对补体第四成分活性及理化性质的影响
J Exp Med. 1965 May 1;121(5):819-33. doi: 10.1084/jem.121.5.819.
9
Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.人血浆α2-巨球蛋白。一种血浆激肽释放酶抑制剂。
J Exp Med. 1970 Aug 1;132(2):329-52. doi: 10.1084/jem.132.2.329.
10
Effect of C'1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema.C'1酯酶对人体血管通透性的影响：在正常个体、补体缺陷个体及遗传性血管性水肿患者中的研究。
J Clin Invest. 1968 Mar;47(3):604-11. doi: 10.1172/JCI105756.

引用本文的文献

1
The complement system in human pregnancy and preeclampsia.人类妊娠和子痫前期中的补体系统。
Front Immunol. 2025 Aug 19;16:1617140. doi: 10.3389/fimmu.2025.1617140. eCollection 2025.
2
Patterns of C1-Inhibitor Plasma Levels and Kinin-Kallikrein System Activation in Relation to COVID-19 Severity.与新冠病毒疾病严重程度相关的C1抑制物血浆水平及激肽-激肽释放酶系统激活模式
Life (Basel). 2024 Nov 21;14(12):1525. doi: 10.3390/life14121525.
3
Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.静脉血栓栓塞症概述及基于纳米载体药物传递系统的新兴治疗技术
Molecules. 2024 Oct 15;29(20):4883. doi: 10.3390/molecules29204883.
4
Potential Pathways and Pathophysiological Implications of Viral Infection-Driven Activation of Kallikrein-Kinin System (KKS).病毒感染驱动激肽释放酶-激肽系统（KKS）激活的潜在途径和病理生理学意义。
Viruses. 2024 Feb 3;16(2):245. doi: 10.3390/v16020245.
5
High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism.血浆 C1 抑制剂水平高与未来静脉血栓栓塞风险降低相关。
J Thromb Haemost. 2023 Jul;21(7):1849-1860. doi: 10.1016/j.jtha.2023.03.024. Epub 2023 Mar 31.
6
Combined anti-C1-INH and radiotherapy against glioblastoma.联合抗 C1-INH 与放疗治疗脑胶质瘤。
BMC Cancer. 2023 Jan 30;23(1):106. doi: 10.1186/s12885-023-10583-1.
7
Coagulation and complement: Key innate defense participants in a seamless web.凝血与补体：无缝网络中的固有防御关键参与者。
Front Immunol. 2022 Aug 9;13:918775. doi: 10.3389/fimmu.2022.918775. eCollection 2022.
8
Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation.肾素-血管紧张素、补体和激肽释放酶-激肽系统在炎症中的相互作用。
Nat Rev Immunol. 2022 Jul;22(7):411-428. doi: 10.1038/s41577-021-00634-8. Epub 2021 Nov 10.
9
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.血栓炎症支持 COVID-19 癌症患者的补体激活。
Front Immunol. 2021 Aug 18;12:716361. doi: 10.3389/fimmu.2021.716361. eCollection 2021.
10
Assessing Plasmin Generation in Health and Disease.评估健康和疾病中的纤溶酶生成。
Int J Mol Sci. 2021 Mar 9;22(5):2758. doi: 10.3390/ijms22052758.

本文引用的文献

1
INCREASED VASCULAR PERMEABILITY INDUCED BY HUMAN PLASMIN.人纤溶酶诱导的血管通透性增加。
J Exp Med. 1965 Oct 31;122(5):905-21. doi: 10.1084/jem.122.5.905.
2
A STUDY OF ANTIFIBRINOLYSIN ACTIVITY IN THE PLASMAS OF VARIOUS ANIMAL SPECIES.不同动物物种血浆中抗纤维蛋白溶酶活性的研究。
J Clin Invest. 1948 Nov;27(6):785-92. doi: 10.1172/JCI102029.
3
Partial purification and properties of a proteolytic enzyme of human serum.人血清中一种蛋白水解酶的部分纯化及性质
J Biol Chem. 1949 Nov;181(1):431-48.
4
Interrelations between different mechanisms of release of biologically active peptides from blood plasma.血浆中生物活性肽不同释放机制之间的相互关系。
Nature. 1962 May 26;194:749-51. doi: 10.1038/194749a0.
5
Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.遗传性血管性水肿。II. 血清球蛋白通透性因子和/或血浆激肽释放酶抑制剂缺乏。
J Allergy. 1962 Jul-Aug;33:330-41. doi: 10.1016/0021-8707(62)90032-1.
6
[Role of the contact factor (Hageman factor) in fibrinolysis].[接触因子（哈格曼因子）在纤维蛋白溶解中的作用]
Thromb Diath Haemorrh. 1959 Sep 1;3:593-603.
7
Assay and properties of serum inhibitor of C'l-esterase.C1酯酶血清抑制剂的测定与特性
Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608-11. doi: 10.3181/00379727-101-25034.
8
Purification of thrombin by chromatography.通过色谱法纯化凝血酶。
Biochim Biophys Acta. 1955 Jan;16(1):157-8. doi: 10.1016/0006-3002(55)90194-3.
9
Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. I. An activable permeability factor and its inhibitor in guinea-pig serum.血清中类似酶的球蛋白再现炎症的血管现象。I. 豚鼠血清中的一种可激活的通透性因子及其抑制剂。
Br J Exp Pathol. 1955 Feb;36(1):71-81.
10
THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR.活化的哈格曼因子诱导人血浆中通透性增加活性
Br J Exp Pathol. 1964 Jun;45(3):328-45.

血清C'1酯酶抑制剂对纤溶酶、血浆激肽释放酶、血浆通透因子及补体第一成分的C'1r亚成分的抑制作用。

The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

作者信息

Ratnoff O D, Pensky J, Ogston D, Naff G B

出版信息

J Exp Med. 1969 Feb 1;129(2):315-31. doi: 10.1084/jem.129.2.315.

DOI:10.1084/jem.129.2.315
PMID:4178758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2138601/
Abstract

The fraction of human serum designated as C'1 esterase inhibitor is known to inhibit the action of C'1 esterase, a plasma kallikrein, and PF/Dil, an enzyme in plasma enhancing cutaneous vascular permeability. In the present study, C'1 esterase inhibitor has been found to block the actions of plasmin and the C'1r subcomponent of the first component of complement, and to retard the generation of PF/Dil. No inhibition of blood clotting or of the generation of plasmin was demonstrable.

摘要

已知人血清中被称为C'1酯酶抑制剂的部分可抑制C'1酯酶、血浆激肽释放酶以及血浆中一种增强皮肤血管通透性的酶PF/Dil的作用。在本研究中，已发现C'1酯酶抑制剂可阻断纤溶酶和补体第一成分的C'1r亚成分的作用，并延缓PF/Dil的产生。未证实其对血液凝固或纤溶酶生成有抑制作用。